Skip to content

A clinical study to evaluate the effect of Unani drug in the Treatment of Chronic Cervicitis

A clinical evaluation of polyherbal formulation in the management of Warm -e- unq-ur-rahem muzmin (Chronic Cervicitis)-An open label single arm study. - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065064
Enrollment
40
Registered
2024-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N72- Inflammatory disease of cervix uteri

Interventions

Intervention1: Extract of Unani polyherbal formulation Neem (Azadirachta indica) Mundi( Sphaeranthus indicus linn) Kasni (Chicorium intybus) Methi (Trigonella foenum) Revandchini (Rheum emodi) Mazoo (

Sponsors

Ayurvedic and Unani Tibbia college and hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Married women in the age group of 18 to 45 years having vaginal discharge. 2. Patient giving history or complaint of the passage of mucopurulent cervical discharge with or without foul smell. 3. Patient with complaints of lower backache. 4. Patient with complaints of intermenstrual spotting and post-coital bleeding. 6. Patient having symptoms of dyspareunia and dysuria. 7. Patient having complaints of vulval Itching. 8. On P/S examination there may be findings of Nabothian follicles, congestion, and hyperplasia of cervix.

Exclusion criteria

Exclusion criteria: 1. The patient was unwilling to sign the consent form. 2. The patient has a history of AIDS, syphilis, gonorrhea or any other sexually transmitted disease. 3. History of cardiovascular, renal, liver disease. 4. History of diabetes mellitus . 5. Patients with systemic disease and malignancy. 6. Individuals of alcohol abuse or any other substance abuse. 7. Unmarried and pregnant women. 8. Women having a history of conisation, cryotherapy, and cauterization will also excluded.

Design outcomes

Primary

MeasureTime frame
VAS Score (visual analogue scale),PS/PV Examination and PAP Smear will be assessed Timepoint: 12 weeks

Secondary

MeasureTime frame
Abnormal cervical discharge, Lower backache, Vulval Itching, Foul smell in Vaginal Discharge will be assessed Timepoint: 12 weeks

Countries

India

Contacts

Public ContactDr.Tanzeela khan

Ayurvedic and Unani tibbia college and hospital

shahanaayub86@gmail.com8077530209

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026